Henri Leinonen

My laboratory´s research focuses on two projects: (1) investigation of a novel drug repurposing-strategy for the treatment of retinal degenerations (RD); (2) Homeostatic plasticity in the retina, its molecular mechanisms and implications for functional adaptation.

Our drug discovery program uses repurposed GPCR drugs. We have shown that a treatment with a combination therapy comprised of three GPCR-drugs slows progressive RD. The next crucial task is to uncover the therapeutic mechanisms of our therapy. This will facilitate further development of the treatment concept, launch innovative drug development pipelines, as well as advance the concept to clinical evaluation.

We use the retina as a model tissue for plasticity, pharmacology and drug discovery research for several reasons, such as amenability for noninvasive imaging due to eye’s transparency, finely layered structure and well-characterized structure-function relationships, functional similarity to that of brain due to same neurodevelopmental origin. Arguably, the retina is the best-characterized neuronal system in the body.